Skip to main content
P

Plumbline Life Sciences, Inc. — Investor Relations & Filings

Ticker · 222670 ISIN · KR7222670002 KO Manufacturing
Open in API
Filings indexed 219 across all filing types
Latest filing 2025-03-26 Declaration of Voting R…
Country KR South Korea
Listing KO 222670

About Plumbline Life Sciences, Inc.

http://www.plsdna.com/

Plumbline Life Sciences, Inc. is an animal biopharmaceutical company that develops and manufactures drugs for animals based on an innovative DNA medicine platform technology. The company creates a new class of nucleic acid-based medicines that are designed to be potent, safe, and stable at room temperature, with a simplified manufacturing process. Its pipeline is focused on two primary areas: therapeutics for companion animals and vaccines for farm animals. A key product is 'RenewDog', a first-in-class DNA therapeutic developed for aging dogs.

Recent filings

Filing Released Lang Actions
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is titled '정기주주총회 결과' (Regular General Meeting of Shareholders Results) and provides a detailed breakdown of the agenda items voted upon (financial statements, director re-election, compensation limits, etc.) and their outcomes (approved). This is a formal declaration of voting results from a general meeting, which fits the definition of DVA (Declaration of Voting Results & Voting Rights Announcements).
2025-03-26 Korean
주식매수선택권부여에관한신고
Remuneration Information Classification · 1% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on the Granting of Stock Options) submitted to the Financial Services Commission/Korea Exchange. It details the issuance of stock options to directors and employees, including the number of shares, exercise price, and vesting conditions. This type of disclosure regarding capital structure changes and equity-based compensation falls under the category of 'Share Issue/Capital Change' (SHA) in the provided classification schema.
2025-03-26 Korean
증권발행결과(자율공시) (제3자배정 유상증자)
Share Issue/Capital Change Classification · 1% confidence The document is a formal announcement regarding the results of a third-party capital increase (share issuance) by Plumline Life Sciences. It details the number of shares issued, the amount raised, and the payment date. This falls under the category of share issuance and capital changes.
2025-03-20 Korean
사업보고서 (2024.12)
Audit Report / Information Classification · 1% confidence The document is a formal 'Audit Report' (감사보고서) for the company 'Plumline Life Sciences' (주식회사 플럼라인생명과학) for the fiscal year ending December 31, 2024. It includes the independent auditor's opinion, financial statements (Balance Sheet, Income Statement, Statement of Changes in Equity, Cash Flow Statement), and detailed notes to the financial statements. This is a comprehensive financial audit document, not an annual report (10-K) which typically includes management discussion and analysis, business strategy, and other non-financial disclosures, nor is it a simple earnings release. Therefore, it is classified as an Audit Report. FY 2024
2025-03-19 Korean
감사보고서제출
Audit Report / Information Classification · 1% confidence The document is a formal announcement titled '감사보고서 제출' (Submission of Audit Report) by Plumline Life Sciences. It provides a summary of the audit opinion (unqualified/appropriate), key financial data (assets, liabilities, net income), and the name of the accounting firm. While it contains financial data, it is a regulatory disclosure announcing the receipt and submission of the audit report, which is a standard requirement for public companies in Korea. This fits the definition of an Audit Report/Information (AR) filing as it provides the audit results and financial summary. FY 2024
2025-03-18 Korean
[기재정정]주요사항보고서(유상증자결정)
Share Issue/Capital Change Classification · 1% confidence The document is a 'Major Matter Report' (주요사항보고서) regarding a decision on paid-in capital increase (유상증자결정) and a subsequent correction (정정신고) for Plumline Life Sciences. This document details the issuance of new shares, the purpose of the capital raise, and the specific terms of the third-party allocation. In the context of financial filings, announcements regarding capital changes, share issues, and capital structure adjustments are classified as 'Share Issue/Capital Change'.
2025-03-13 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.